DE2317768C3 - Verfahren zur Herstellung eines antazid wirkenden Arzneimittels - Google Patents
Verfahren zur Herstellung eines antazid wirkenden ArzneimittelsInfo
- Publication number
- DE2317768C3 DE2317768C3 DE2317768A DE2317768A DE2317768C3 DE 2317768 C3 DE2317768 C3 DE 2317768C3 DE 2317768 A DE2317768 A DE 2317768A DE 2317768 A DE2317768 A DE 2317768A DE 2317768 C3 DE2317768 C3 DE 2317768C3
- Authority
- DE
- Germany
- Prior art keywords
- effect
- value
- process step
- water
- secretive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 68
- 239000003159 antacid agent Substances 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 230000008569 process Effects 0.000 title description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 54
- 239000000047 product Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 23
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 19
- 239000001095 magnesium carbonate Substances 0.000 claims description 18
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 239000006185 dispersion Substances 0.000 claims description 17
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 15
- 229940069428 antacid Drugs 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- 230000001458 anti-acid effect Effects 0.000 claims description 10
- 210000004051 gastric juice Anatomy 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 10
- 230000003472 neutralizing effect Effects 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 230000003139 buffering effect Effects 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 102000057297 Pepsin A Human genes 0.000 claims description 7
- 108090000284 Pepsin A Proteins 0.000 claims description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- 229940111202 pepsin Drugs 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 239000000395 magnesium oxide Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- 206010048714 Gastroduodenitis Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 206010020601 Hyperchlorhydria Diseases 0.000 claims description 3
- 239000006227 byproduct Substances 0.000 claims description 3
- BUACSMWVFUNQET-UHFFFAOYSA-H dialuminum;trisulfate;hydrate Chemical compound O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BUACSMWVFUNQET-UHFFFAOYSA-H 0.000 claims description 3
- -1 hydrogen ions Chemical class 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- VTYCBVOPODCEFZ-UHFFFAOYSA-L magnesium;carbonate;pentahydrate Chemical compound O.O.O.O.O.[Mg+2].[O-]C([O-])=O VTYCBVOPODCEFZ-UHFFFAOYSA-L 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 230000009858 acid secretion Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 150000002681 magnesium compounds Chemical class 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 229940099273 magnesium trisilicate Drugs 0.000 claims 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims 1
- 235000019793 magnesium trisilicate Nutrition 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 11
- 238000001035 drying Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000003860 storage Methods 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005213 imbibition Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000024981 pyrosis Diseases 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT6813972 | 1972-04-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2317768A1 DE2317768A1 (de) | 1973-10-25 |
| DE2317768B2 DE2317768B2 (de) | 1978-10-26 |
| DE2317768C3 true DE2317768C3 (de) | 1979-06-21 |
Family
ID=11308103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2317768A Expired DE2317768C3 (de) | 1972-04-13 | 1973-04-09 | Verfahren zur Herstellung eines antazid wirkenden Arzneimittels |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3857938A (enExample) |
| JP (1) | JPS5551849B2 (enExample) |
| DE (1) | DE2317768C3 (enExample) |
| ES (1) | ES413371A1 (enExample) |
| FR (1) | FR2187358B1 (enExample) |
| GB (1) | GB1363399A (enExample) |
| NL (1) | NL168135C (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4059681A (en) * | 1973-05-14 | 1977-11-22 | Purdue Research Foundation | Stable dried aluminum hydroxide gel |
| DE2750346A1 (de) * | 1977-11-10 | 1979-05-17 | Purdue Research Foundation | Verfahren zur herstellung eines trockenen, amorphen aluminiumhydroxidgel-antazidums, aluminiumhydroxidgel und arzneimittel |
| DE3019032C2 (de) * | 1980-05-19 | 1983-09-01 | Gödecke AG, 1000 Berlin | Antacider Wirkstoff auf Magnesium-Aluminiumhydroxid-Basis, seine Herstellung und Verwendung |
| US4915957A (en) * | 1980-05-19 | 1990-04-10 | Godecke Aktiengesellschaft | Antacid material |
| DE3306822C2 (de) * | 1983-02-26 | 1985-01-03 | Giulini Chemie Gmbh, 6700 Ludwigshafen | Kristallines, basisches Aluminium-Magnesium-Carbonat |
| DE3408463C2 (de) * | 1984-03-08 | 1987-02-26 | Giulini Chemie Gmbh, 6700 Ludwigshafen | Verfahren zur Herstellung einer aluminium- und magnesiumhaltigen Verbindung der Formel Al↓5↓Mg↓1↓↓0↓ (OH)↓3↓↓1↓ (SO↓4↓)↓2↓ . x H↓2↓O |
| DE3586281T2 (de) * | 1984-04-19 | 1992-12-10 | Rhone Poulenc Rorer Int | Antisaeurezusammensetzung. |
| US4869902A (en) * | 1984-04-19 | 1989-09-26 | Rorer Pharmaceutical Corporation | Antacid composition |
| JP2001501224A (ja) * | 1996-10-04 | 2001-01-30 | メルク エンド カンパニー インコーポレーテッド | 胸焼けを予防及び治療するための方法及び組成物 |
| GB0807621D0 (en) | 2008-04-25 | 2008-06-04 | Ineos Healthcare Ltd | Use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2194895A (en) * | 1937-04-14 | 1940-03-26 | Jenkins Bros | Valve stem |
| US2880136A (en) * | 1953-11-13 | 1959-03-31 | Macleans Ltd | Co-precipitate of aluminium hydroxide with magnesium carbonate and/or calcium carbonate |
| US2797978A (en) * | 1956-01-04 | 1957-07-02 | Reheis Company Inc | Aluminum and magnesium hydroxy carbonate |
| US3239416A (en) * | 1963-05-29 | 1966-03-08 | Armour Pharma | Aluminum hydroxide-metal hydroxide antacid and process of making the same |
| US3272704A (en) * | 1963-06-06 | 1966-09-13 | Armour Pharma | Stable aluminum hydroxide-magnesium compound codried gel antacids and process of making the same |
| US3539306A (en) * | 1966-07-25 | 1970-11-10 | Kyowa Chem Ind Co Ltd | Process for the preparation of hydrotalcite |
| GB1236880A (en) * | 1969-12-20 | 1971-06-23 | Exp Drugs Company | Antacid compositions |
-
1973
- 1973-04-04 GB GB1619273A patent/GB1363399A/en not_active Expired
- 1973-04-05 ES ES413371A patent/ES413371A1/es not_active Expired
- 1973-04-09 DE DE2317768A patent/DE2317768C3/de not_active Expired
- 1973-04-12 FR FR7313311A patent/FR2187358B1/fr not_active Expired
- 1973-04-12 JP JP4175373A patent/JPS5551849B2/ja not_active Expired
- 1973-04-13 NL NLAANVRAGE7305230,A patent/NL168135C/xx not_active IP Right Cessation
- 1973-04-13 US US00350866A patent/US3857938A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES413371A1 (es) | 1976-06-01 |
| NL168135C (nl) | 1982-03-16 |
| JPS4947518A (enExample) | 1974-05-08 |
| NL168135B (nl) | 1981-10-16 |
| US3857938A (en) | 1974-12-31 |
| NL7305230A (enExample) | 1973-10-16 |
| DE2317768B2 (de) | 1978-10-26 |
| FR2187358A1 (enExample) | 1974-01-18 |
| JPS5551849B2 (enExample) | 1980-12-26 |
| DE2317768A1 (de) | 1973-10-25 |
| GB1363399A (en) | 1974-08-14 |
| FR2187358B1 (enExample) | 1976-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1617374C2 (de) | Verfahren zum Herstellen eines pharmazeutischen Präparates mit verzögerter analgetischer Wirkung | |
| DE3406127C2 (enExample) | ||
| DE1592126A1 (de) | Verfahren zur Herstellung von Hydrotalkit | |
| DE2907215A1 (de) | Feste depotarzneimittelpraeparate und verfahren zu deren herstellung | |
| DE69128760T2 (de) | Antidiarrhoeika | |
| DE2332484A1 (de) | Lutschpastillen mit verzoegerter freigabe | |
| DE1916535B2 (de) | Komplexe aus wasserlöslichen Salzen von sulfatierten Polysacchariden und basischen Aluminiumsalzen und Verfahren zu deren Herstellung | |
| DE2317768C3 (de) | Verfahren zur Herstellung eines antazid wirkenden Arzneimittels | |
| DE2936078C2 (de) | Synthetisches Magnesiumaluminiumsilikat und dieses enthaltendes pharmazeutisches Präparat | |
| EP0471967A1 (de) | Sucralfat-Kautablette | |
| DE3019032C2 (de) | Antacider Wirkstoff auf Magnesium-Aluminiumhydroxid-Basis, seine Herstellung und Verwendung | |
| DE3203310C2 (enExample) | ||
| DE69919963T2 (de) | Magnesiumoxid enthaltendes Abführmittel | |
| EP0286781A2 (de) | Pharmazeutische Zubereitung zur Behandlung von Erkrankungen des Magen-Darm-Traktes | |
| DE69201077T2 (de) | Alginsäure enthaltende Arzneisuspension. | |
| DE2342460A1 (de) | Eisen- oder aluminiumglycyrrhizinat enthaltendes produkt, verfahren zu seiner herstellung und dieses produkt enthaltendes arzneimittel | |
| DE69100053T2 (de) | Arzneimittelzusammensetzung in stabiler wässriger Suspensionsform auf der Basis von Sucralfat und einem Antacidum sowie Verfahren zu ihrer Herstellung. | |
| DE2446640A1 (de) | Neue gentamicinderivate, verfahren zur herstellung derselben und diese enthaltende antibiotisch wirksame zusammensetzungen | |
| DE3315606C2 (enExample) | ||
| DE2047049C3 (de) | Calciumsalz der 6-(N-Acetylamino)hexansSure, Verfahren zu seiner Herstellung und Arzneimittel mit einem Gehalt an diesem Salz | |
| CH642545A5 (de) | Mittel gegen magensaeure, verfahren zu seiner herstellung und dieses mittel enthaltende, arzneimittelzubereitung. | |
| DE1617277C3 (de) | Verfahren zur Herstellung eines flüssigen Antazidums | |
| CH403798A (de) | Verfahren zur Herstellung eines Amprotropin enthaltenden Arzneimittels | |
| DE1593765A1 (de) | Chelatkomplexverbindung,Verfahren zu ihrer Herstellung,sowie diese Verbindung enthaltende pharmazeutische Praeparate | |
| DE1274276B (de) | Stabile waessrige antacide Suspension von Aluminiumhydroxyd und Magnesiumhydroxyd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |